Previous 10 | Next 10 |
LA JOLLA, Calif. , June 11, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Jake Nunn and Simos Simeonidis , Ph.D. have been appoint...
Regulus Therapeutics (NASDAQ: RGLS ) is 4% lower postmarket after a shareholder filing to offer 27.8M shares of the company. More news on: Regulus Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...
Outlook Therapeutics (NASDAQ: OTLK ) +26% as the company is poised to add to ONS-5010. More news on: Outlook Therapeutics, Inc., Orion Energy Systems, Inc, Sprint Corporation, Stocks on the move, Read more ...
Messenger RNA therapeutics company, moderna ( MRNA ), if successful, could completely transform modern medicine. We're talking a potential paradigm-shift here. They're using messenger RNA (mRNA) to treat a variety of diseases with their three programs covering immuno-oncology, vaccines for u...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Regulus Therapeutics (NASDAQ: RGLS ): Q1 GAAP EPS of -$0.31. More news on: Regulus Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
LA JOLLA, Calif. , May 9, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first q...
LA JOLLA, Calif. , May 7, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the closing of the first tranche of its previously annou...
Gainers: Aquantia (NYSE: AQ ) +36% . Sinclair Broadcast (NASDAQ: SBGI ) +28% . Athenex (NASDAQ: ATNX ) +25% . Bridgeline Digital (NASDAQ: BLIN ) +22% . Regulus Therapeutics (NASDAQ: RGLS ) +18% . Ovid Therapeutics (NASDAQ: OVID ) +17% . Daxor Corporation (NYSEMKT: DXR ) +17% ....
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...